BlueLight Therapeutics

BlueLight Therapeutics utilizes a proprietary structure-driven platform to develop novel therapeutic molecules targeting challenging high-value drug targets. We have a passionate and experienced team with unique expertise in structural analysis for a wide range of target classes. Our proprietary platform leverages second harmonic generation (SHG) to measure structural changes in biomolecules in real-time and at high throughput. Biomolecules undergo conformational changes that modulate activity and influence their interactions with other molecules in pathways. By combining knowledge of the native and disease-relevant biology of drug targets with our platform, we can efficiently discover and develop molecules that induce functionally relevant structural changes in difficult-to-drug targets. As a result, our drugs treat diseases by inducing desired conformational states in key targets.